VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Recruiting now · Phase 1/Phase 2

Conditions studied: Higher-risk Myelodysplastic Syndromes

In brief

The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.

Key facts

Study ID

NCT06471946

Run by

Navy General Hospital, Beijing

People needed

54

Starts

2024-10-01

Expected to finish

2030-09-01

Last updated by the study team

2024-10-01

Who can join

Age: 70 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.
• The patient is willing and able to adhere to the study visit schedule and other protocol requirements.
• The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO).

You may not qualify if…

• Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.
• Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.

Where it is running

• Navy General Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.